Suchergebnisse - "Weis, Nina"

PubPharm (10)

1

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1 : week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

enthalten in: The lancet. HIV | 2024

von Orkin, C. | Molina, J. | Cahn, P. | +112

2

Amantadine for COVID-19 treatment (ACT) study : a randomized, double-blinded, placebo-controlled clinical trial

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2023

von Weis, N. | Bollerup, S. | Sund, J. | +6

3

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence : the randomized phase 2a TITAN trial

enthalten in: Nature medicine | 2023

von Gunst, J. | Højen, J. | Pahus, M. | +30

4

Effect of PEP flute self-care versus usual care in early covid-19 : non-drug, open label, randomised controlled trial in a Danish community setting

enthalten in: BMJ (Clinical research ed.) | 2021

von Mollerup, A. | Henriksen, M. | Larsen, S. | +7

5

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD) : 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

enthalten in: The lancet. HIV | 2020

von Molina, J. | Squires, K. | Sax, P. | +112

CommentIn: Lancet HIV. 2020 Jan;7(1):e2-e3. - PMID 31740350

6

Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals : a clinical randomized study

enthalten in: European journal of gastroenterology & hepatology | 2018

von Sølund, C. | Andersen, E. | Mössner, B. | +10

7

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD) : 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2018

von Molina, J. | Squires, K. | Sax, P. | +113

CommentIn: Lancet HIV. 2018 May;5(5):e200-e201. - PMID 29592841

8

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection : a randomised study

enthalten in: Gut | 2015

von Hézode, C. | Hirschfield, G. | Ghesquiere, W. | +31

9

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY) : a randomised, open-label phase 2 trial

enthalten in: Lancet (London, England) | 2015

von Sulkowski, M. | Hezode, C. | Gerstoft, J. | +20

CommentIn: Lancet. 2015 Mar 21;385(9973):1050-2. - PMID 25468162

10

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection

enthalten in: Gastroenterology | 2015

von Dore, G. | Lawitz, E. | Hézode, C. | +24

1
[1]